Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LYON, France, Sept. 10, 2009 (GLOBE NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the expansion of Ablatherm-HIFU into new territories as part...
-
Second Quarter 2009 Highlights: * Year-over-year comparisons -- Total revenue of EUR 6.8 million, up 37.0% -- Total HIFU revenue of EUR 2.2 million, up 34.2% -- Ablatherm-HIFU revenue...
-
LYON, France, Aug. 19, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration has granted 510(k)...
-
LYON, France, Aug. 12, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2009 earnings...
-
LYON, France, July 16, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Rob Michiels was appointed to its Board of Directors,...
-
U.S. Urologist Dr. Douglas Chinn Named Clinical Instructor First Ablatherm-HIFU Patient Treated At Memorial Sloan-Kettering Cancer...
-
LYON, France, June 26, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Dr. Argil J. Wheelock, MD was appointed to its Board of...
-
LYON, France, June 18, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was...
-
Receives Ablatherm-HIFU Approval in Argentina Signs Exclusive Distribution Agreements in Argentina, Brazil and Chile LYON, France, June 2, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA...
-
First Quarter 2009 Highlights: * FDA agreed changes to HIFU clinical trial protocol to accelerate enrollment * Continuing dialogue with FDA for further changes to ensure timely completion...